

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.
Petitioner,

v.

BAUSCH HEALTH IRELAND LIMITED,
Patent Owner.

IPR2022-00722
Patent No. 7,041,786

DECLARATION OF BLAKE R. PETERSON, PH.D.

TABLE OF CONTENTS

	Page
I. QUALIFICATIONS.....	1
II. SCOPE OF WORK	4
III. LEGAL STANDARDS	5
IV. OVERVIEW OF SHAILUBHAI.....	7
A. Claims of Shailubhai	12
B. Prosecution History of Shailubhai.....	13
V. LEVEL OF ORDINARY SKILL.....	14
VI. CLAIM CONSTRUCTION	15
VII. THE STATE OF THE ART	16
A. Peptide Hormones in the Body and in Medicine.....	16
B. Biochemistry Foundation	20
C. Biology of Human Uroguanylin.....	23
D. The Availability of Solid-Phase Peptide Synthesis for Preparation of Synthetic Analogs of Peptide Hormones.....	30
E. Strategies for Engineering Peptides	34
F. Assays for Measuring Therapeutic Activity for Clinical Constipation Were Well-Known in the Art.....	39
G. Formulating Peptides with Intestinal Targets for Oral Delivery.....	49
H. Treating Constipation and Inflammation	52
VIII. THE ASSERTED REFERENCES DISCLOSE OR SUGGEST EACH OF THE CLAIMED FEATURES OF SHAILUBHAI.....	53
A. Currie	53
B. Li.....	55
C. Narayani.....	56
D. Campieri	57
E. Ekwuribe.....	58
IX. GROUND 1. CLAIM 1 WAS OBVIOUS OVER CURRIE AND LI.....	58

A.	Currie Suggests Uroguanylins For Treating Constipation	63
B.	Reason to Look to Synthetic Analogs of Human Uroguanylin	66
C.	Currie and Li Suggest a Glu ³ Substitution as in Rat Uroguanylin	69
D.	The Known Chemical Properties of Uroguanylins and Amino Acids Would Have Further Provided a Skilled Artisan with a Reasonable Expectation of Improving Constipation-Related Activity through Glu ³ Substitution	77
E.	Routine and Conventional Testing of Synthetic Analogs	85
F.	The Known Issue of Aspartimide Formation in Solid-Phase Peptide Synthesis Would Have Further Supported a Glu ³ Analog of Human Uroguanylin	86
G.	Minimal Difference Between Currie’s Human Uroguanylin and the Claimed [Glu ³]-Human Uroguanylin.	87
X.	GROUND 2. CLAIMS 2, 4, AND 5 WERE OBVIOUS OVER CURRIE, LI, AND NARAYANI	88
A.	Formulating [Glu ³]-Human Uroguanylin in a Unit Dose Form as Recited in Claim 2 Was Obvious	93
B.	Formulating [Glu ³]-Human Uroguanylin in a Capsule as Recited in Claim 4 Was Obvious	97
C.	Formulating [Glu ³]-Human Uroguanylin in a Unit Dose Form along with One or More Excipients as Recited in Claim 5 Was Obvious	98
XI.	GROUND 3. CLAIMS 3-5 WERE OBVIOUS OVER CURRIE, LI, NARAYANI, AND CAMPIERI	100
A.	Formulating [Glu ³]-Human Uroguanylin in a Unit Dose Form as Recited in Claim 3 Was Obvious	103
B.	Formulating [Glu ³]-Human Uroguanylin with an Anti-Inflammatory Agent in a Capsule with One or More Excipients as Recited in Claims 4 and 5 Would Have Been Obvious	107
XII.	GROUND 4. CLAIM 6 WAS OBVIOUS OVER CURRIE, LI, AND EKWURIBE	108
XIII.	SECONDARY CONSIDERATIONS	116
XIV.	CONCLUDING STATEMENTS	119

XV. APPENDIX – LIST OF EXHIBITS121

I, Blake R. Peterson, declare as follows:

I. QUALIFICATIONS

1. I am the John W. Wolfe Chair in Cancer Research with a focus on Medicinal Chemistry and Chemical Biology at The Ohio State University (OSU). I have held faculty appointments from 1998 to the present. My research for over two decades has been directed toward understanding and developing small molecule probes for biological systems. This research included the development of small molecules and peptides that promote cellular uptake of proteins, the synthesis and evaluation of antiviral agents and anticancer agents, the identification of biological targets of small molecules, and the construction of new types of fluorescent probes for immunology and cancer biology.

2. I also currently serve as a Professor of Medicinal Chemistry and Pharmacognosy at OSU, as well as Chair of the Division of Medicinal Chemistry and Pharmacognosy at OSU. I also serve as Co-Leader of the Translational Therapeutics Program of the OSU Comprehensive Cancer Center (CCC) and as Co-Director of the Medicinal Chemistry Shared Resource of the OSU CCC.

3. I previously served as a Regents Distinguished Professor in the Department of Medicinal Chemistry at the University of Kansas (KU) School of Pharmacy from 2008-2019. I also served for seven years as Co-Leader of the Synthetic Chemical Biology Core Facility at the KU.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.